Julien Gautier

722 total citations
21 papers, 356 citations indexed

About

Julien Gautier is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Cancer Research. According to data from OpenAlex, Julien Gautier has authored 21 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 5 papers in Gastroenterology and 5 papers in Cancer Research. Recurrent topics in Julien Gautier's work include Sarcoma Diagnosis and Treatment (6 papers), Gastrointestinal Tumor Research and Treatment (5 papers) and Cancer Genomics and Diagnostics (5 papers). Julien Gautier is often cited by papers focused on Sarcoma Diagnosis and Treatment (6 papers), Gastrointestinal Tumor Research and Treatment (5 papers) and Cancer Genomics and Diagnostics (5 papers). Julien Gautier collaborates with scholars based in France, Italy and Germany. Julien Gautier's co-authors include Alain Ravaud, Stéphane Oudard, Corinne Balleyguier, Bernard Escudier, Chantal Célier, S. Négrier, Jacques Médioni, David Pérol, Sylvie Négrier and Claire Cropet and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and The Journal of Urology.

In The Last Decade

Julien Gautier

19 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julien Gautier France	8	279	181	135	78	58	21	356
Won Jin Chang South Korea	12	110 0.4×	79 0.4×	91 0.7×	14 0.2×	177 3.1×	27	353
Carlos Eduardo Jacob Brazil	12	197 0.7×	82 0.5×	61 0.5×	129 1.7×	95 1.6×	31	457
Carlo Barone Italy	13	200 0.7×	66 0.4×	40 0.3×	63 0.8×	210 3.6×	20	394
Michela Lia Italy	9	249 0.9×	112 0.6×	70 0.5×	11 0.1×	147 2.5×	15	328
Melissa Dinolfo United States	5	159 0.6×	106 0.6×	33 0.2×	24 0.3×	214 3.7×	7	363
Jacopo Giuliani Italy	12	194 0.7×	39 0.2×	48 0.4×	31 0.4×	206 3.6×	76	391
Hiroshi Wataya Japan	14	358 1.3×	101 0.6×	33 0.2×	9 0.1×	289 5.0×	41	558
Łukasz Liszka Poland	13	106 0.4×	58 0.3×	38 0.3×	95 1.2×	159 2.7×	39	423
Hiroyuki Asama Japan	13	164 0.6×	45 0.2×	50 0.4×	52 0.7×	165 2.8×	68	403

Countries citing papers authored by Julien Gautier

Since Specialization

Citations

This map shows the geographic impact of Julien Gautier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Gautier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Gautier more than expected).

Fields of papers citing papers by Julien Gautier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Gautier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Gautier. The network helps show where Julien Gautier may publish in the future.

Co-authorship network of co-authors of Julien Gautier

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Gautier. A scholar is included among the top collaborators of Julien Gautier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Gautier. Julien Gautier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gautier, Julien, et al.. (2025). Clinical benefit of adding cyanoacrylate glue during PICC line insertion compared to standard procedure in outpatient cancer patients: Results from the randomized prospective trial PICCandGLUE. The Journal of Vascular Access. 959564386–959564386.

Cesne, Axel Le, Claire Cropet, Mehdi Brahmi, et al.. (2024). LBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib. Annals of Oncology. 35. S1265–S1266. 1 indexed citations

Mastroïanni, Bénédicte, Hélène Vanacker, Armelle Vinceneux, et al.. (2024). Qualitative evaluation of motives for acceptance or refusal of early palliative care in patients included in early-phase clinical trials in a French comprehensive cancer center: the PALPHA study. Supportive Care in Cancer. 32(6). 353–353.

Chvetzoff, Gisèle, Bénédicte Mastroïanni, Hélène Vanacker, et al.. (2022). Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative study. BMJ Open. 12(4). e060317–e060317. 2 indexed citations

Leblond, Pierre, Maura Massimino, Martin English, et al.. (2022). Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol. Frontiers in Neurology. 13. 887544–887544. 15 indexed citations

Brahmi, Mehdi, Julien Gautier, Armelle Dufresne, et al.. (2022). REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.. Journal of Clinical Oncology. 40(16_suppl). TPS11585–TPS11585. 2 indexed citations

Goury, Antoine, et al.. (2021). Predictive factors associated with high‐flow nasal cannula success for COVID‐19‐related acute hypoxemic respiratory failure. Health Science Reports. 4(2). e287–e287. 5 indexed citations

Duffaud, Florence, Sylvie Chabaud, Julien Gautier, et al.. (2021). REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and non-chordomas).. Journal of Clinical Oncology. 39(15_suppl). TPS11576–TPS11576. 1 indexed citations

Fouchardière, Christelle de la, Yann Godbert, Cécile Dalban, et al.. (2021). Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. European Journal of Cancer. 157. 153–164. 11 indexed citations

10.

Cesne, Axel Le, Claire Cropet, Julien Gautier, et al.. (2020). LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.. Journal of Clinical Oncology. 38(15_suppl). TPS11568–TPS11568. 2 indexed citations

11.

Brunet, Aurélie, et al.. (2020). Vasculitides and glomerulonephritis associated withStaphylocococcus aureusinfective endocarditis: cases reports and mini-review of the literature. Annals of Medicine. 52(6). 265–274. 4 indexed citations

12.

Thomas, Sophie, Jennifer Limond, Mathilde Chevignard, et al.. (2019). The European Society of Paediatric Oncology Ependymoma-II program Core-Plus model: Development and initial implementation of a cognitive test protocol for an international brain tumour trial. European Journal of Paediatric Neurology. 23(4). 560–570. 5 indexed citations

13.

Lebrun, Delphine, O Toubas, Yohan N’Guyen, et al.. (2018). Pulmonary adverse events related to idelalisib therapy: A single centre experience. Journal of Chemotherapy. 30(5). 318–322. 3 indexed citations

14.

Lebrun, Delphine, Thierry Floch, Aurélie Brunet, et al.. (2017). Severe post-artesunate delayed onset anaemia responding to corticotherapy: a case report. Journal of Travel Medicine. 25(1). 14 indexed citations

15.

Mir, Olivier, Claire Cropet, Maud Toulmonde, et al.. (2016). Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. The Lancet Oncology. 17(5). 632–641. 87 indexed citations

16.

Blay, Jean‐Yves, Mathiéu Molimard, Claire Cropet, et al.. (2015). Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. 33(15_suppl). 10506–10506. 7 indexed citations

17.

Blay, Jean‐Yves, Julien Dômont, Claire Cropet, et al.. (2014). A Randomized Multicentre Phase Ii Study of Pazopanib Plus Best Supportive Care (Bsc) Vs Bsc Alone in Metastatic Gastrointestinal Stromal Tumors (Gist) Resistant to Imatinib and Sunitinib. Annals of Oncology. 25. v1–v1. 1 indexed citations

18.

Négrier, S., Alain Ravaud, Stéphane Oudard, et al.. (2009). Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma. The Journal of Urology. 182(1). 29–34. 126 indexed citations

19.

Négrier, Sylvie, David Pérol, Julien Gautier, et al.. (2008). Analysis of characteristics in patients (pts) with metastatic renal cell cancer (MRCC) who achieved a prolonged benefit from sunitinib or sorafenib. Journal of Clinical Oncology. 26(15_suppl). 16022–16022. 2 indexed citations

20.

Sablin, Marie‐Paule, Corinne Balleyguier, Julien Gautier, et al.. (2007). Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. Journal of Clinical Oncology. 25(18_suppl). 5038–5038. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact